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Planning for a cohort study to investigate the impact
and management of influenza in pregnancy in a
future pandemic
Marian Knight,1* Peter Brocklehurst,2 Pat O’Brien,2
Maria A Quigley1 and Jennifer J Kurinczuk1
1National Perinatal Epidemiology Unit, University of Oxford, Oxford, UK
2Institute for Women’s Health, University College London, London, UK
*Corresponding author marian.knight@npeu.ox.ac.uk
Background: Evidence from the 2009 A/H1N1 influenza pandemic demonstrated that pregnant women
are particularly vulnerable to infection and at an increased risk of death. Active data collection through the
UK Obstetric Surveillance System (UKOSS) about women admitted to hospital during the 2009 A/H1N1
pandemic was used to inform ongoing clinical guidance regarding the use of antiviral treatment for
pregnant women and demonstrated that, in addition to an increased risk of maternal morbidity, influenza
infection in pregnancy is associated with poor perinatal outcomes, including an increased risk of stillbirth
and preterm birth. This evidence influenced the decision to offer routine influenza immunisation to
pregnant women. Even in a non-epidemic period, pregnant women continue to die from influenza.
Objective: To establish, and then to put into hibernation, the study mechanisms needed to mount a rapid
investigation of the impact of pandemic influenza in pregnancy in the event of a newly emerging
pandemic strain.
Design: A new UKOSS cohort study was designed, based on the 2009–10 study, and following
consultation with the Pandemic Flu Planning Group at the Royal College of Obstetricians and
Gynaecologists and the UKOSS Steering Committee, to identify potential previously unanswered questions.
Setting: UK maternity units.
Participants: All pregnant women admitted to hospital with influenza in a future pandemic.
Main outcome measures: Management of pregnant women with influenza infection, intervention rates,
treatment and pregnancy outcome for both the mother and fetus.
Results: The study was designed and approved by the UKOSS Steering Committee and then placed into
hibernation for activation in the event of an influenza pandemic.
Conclusions: Pregnant women, as a result of their changed immunological status, appear to be
particularly susceptible to infection, including from influenza. The existence of the UKOSS enabled us to
rapidly mount a study of pregnant women who were hospitalised with 2009 A/H1N1 influenza. Minor
modifications to incorporate previously unanswered questions and our previous study enabled us to
design, and then put into hibernation, a new study ready to investigate the impact and management of
influenza in pregnancy, which is poised for activation in the event of a newly emerging pandemic strain.
This will enable real-time data to be available on which to base rapid changes in clinical management as
the as-yet-unforeseen pandemic unfolds. In the event of an influenza pandemic the study will be available
to be immediately activated following expedited regulatory approvals.
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Trial registration: Current Controlled Trials ISRCTN44137563.
Funding: The National Institute for Health Research Health Services and Delivery Research programme.
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Plain English summary
P regnant women have an increased chance of developing infections and becoming seriously ill; thisincludes being more likely to catch influenza (flu). During the ‘swine flu’ pandemic of 2009–10 we
carried out a study to investigate the effect of flu on pregnant women using a system called the UK
Obstetric Surveillance System (UKOSS). We set up UKOSS in 2005 to study serious rare conditions affecting
pregnant women, so, when ‘swine flu’ was declared as a pandemic, we rapidly set in place a study to look
at its effects in pregnancy. We found that pregnant women had an increased risk of becoming severely ill
and were also more likely to have a stillborn or premature baby. The results from the study were used to
make changes to the treatment offered to pregnant women infected with ‘swine flu’ and also led to the
recommendation that all pregnant women should receive vaccination against seasonal flu routinely – this is
the flu that occurs every year in winter time. We know that, even though there is not a flu pandemic
currently, a small number of pregnant women have nevertheless died from seasonal flu.
Using our experience from the ‘swine flu’ pandemic we have set everything in place so that if there is
another flu pandemic we can rapidly activate a new UKOSS study to investigate what happens. This will
provide the necessary information, once again, to enable treatment and vaccination provided during
pregnancy to be tailored to the particular needs of pregnant women.
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Chapter 1 Background
Evidence from the last influenza pandemic (2009 A/H1N1) showed that pregnant women wereparticularly vulnerable to severe complications of infection,1–5 resulting in increases in both maternal
and perinatal mortality.5–7 Further investigations, including in the UK,5 highlighted specific groups of
women who were at higher risk of morbidity after 2009 A/H1N1 infection in pregnancy. Factors associated
with admission to hospital with 2009 A/H1N1 in pregnancy included maternal obesity, asthma, multiparity,
multiple pregnancy, black or other minority group ethnicity, and smoking among women aged < 25 years.1,3,5
Women have continued to die from influenza associated with pregnancy seasonally since the pandemic.8
Active data collection on pregnant women at the time of admission to hospital with confirmed 2009
A/H1N1 influenza, as well as identifying particular subgroups who were at risk of the severest disease and
hence a particular target for preventative interventions, also pinpointed aspects of management that
resulted in improved outcomes for women, including the importance of early antiviral treatment.5 In the
2009 pandemic, monthly analysis of emerging data was used to inform ongoing clinical guidance.
Admission to an intensive care unit, taken as a proxy for severe morbidity, was also associated with delay
in starting treatment with antiviral medication (> 2 days after the onset of symptoms) in other population
studies.1,3,4,9 This has been confirmed in more recent meta-analyses of observational data.10
Many studies of 2009 A/H1N1 in pregnancy reported very incomplete outcomes or outcomes for only a
subset of severely affected women.1,3,4,9,11,12 Half of the initial published outcome rates were calculated
using subsamples of < 50% of the study cohort. The majority of studies did not follow up women to the
end of their pregnancy3,4,9,11 or, in some cases, the follow-up time was too short to collect outcome
information on women infected at all gestations.3,6 This approach will have biased any results towards
reporting preterm births and is likely to have led to overly pessimistic results.
The UK study13 followed up 94% of the original study cohort (n= 256) and demonstrated that poor
perinatal outcomes, in addition to poor maternal outcomes, were associated with 2009 A/H1N1 influenza
infection in pregnancy. The risks of poor outcomes persisted after adjustment for maternal and pregnancy
characteristics that were known to be associated with poor perinatal outcomes. The study13 suggested an
increased risk of perinatal mortality in women infected with 2009 A/H1N1 compared with the general
population {perinatal mortality rate 39 per 1000 total births [95% confidence interval (CI) 19 to 71 per
1000 total births] compared with 7 per 1000 total births (95% CI 3 to 13 per 1000 total births), adjusted
odds ratio (aOR)= 5.7; 95% CI 2.2 to 15.1}. This was explained largely by an increased risk of stillbirth,
although the neonatal death rate was also significantly higher than the national rate (odds ratio 3.8,
95% CI 1.2 to 11.8). The study strengthened the evidence for offering routine immunisation to pregnant
women and informed subsequent guidance in Europe.14 More recent cohort studies using routinely
collected data have identified similar findings.15
In addition to the mortality risk, infants were at greater risk of preterm birth (aOR 4.0, 95% CI 2.7 to 5.9);13
this was a mixture of both iatrogenic and spontaneous preterm delivery. The data suggest that women
with 2009 A/H1N1 infection who gave birth preterm were more likely to have been infected in their third
trimester. Secondary infection with bacterial pneumonia played an important role in preterm delivery in this
2009–10 cohort; secondary pneumonia was also associated with preterm birth in women with pandemic
influenza in 1919.16 In the UK data, the risk of preterm birth associated with 2009 A/H1N1 infection
persisted even after accounting for the role of secondary pneumonia, which suggested that the excess risk
could not be explained by this factor alone.13
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Almost half of the infants delivered preterm were delivered early because of maternal compromise.
Women are typically delivered during the third trimester in order to aid mechanical ventilation. However,
emerging evidence suggests that when women are referred for management with extracorporeal
membrane oxygenation (ECMO), in the absence of fetal compromise there may not be an indication to
deliver the fetus early.17 This is noted particularly at gestations of < 30–32 weeks, when the size of the
uterus is unlikely to affect mechanical ventilation. Increased availability and use of ECMO may therefore
have the potential to impact positively on infant outcomes, even in the presence of maternal critical illness,
including not only mortality, but also long-term morbidity, care costs and emotional stress for parents.
Overall, these studies show a clear increase in risk of poor maternal and pregnancy outcomes in women
infected with 2009 A/H1N1 influenza. Importantly, immunisation against 2009 A/H1N1 influenza for
pregnant women was shown to have a significant impact on health outcomes for both mother and baby.14
Almost half of the preterm births were due to early delivery for maternal compromise, indicating that the
health of pregnant women, which is improved with rapid treatment with antiviral agents, is an important
public health priority in future waves of this and other influenza pandemics.
In a future pandemic, however, these observed patterns may differ, and a rapid study of this susceptible
group will be important to inform both ongoing preventative and management policies. In the early period
of the 2009 A/H1N1 pandemic, agencies took time to co-ordinate and agree guidance. There was thus
a delay before any guidance on the care of pregnant or postpartum women with A/H1N1 was issued,
and delays in updating this guidance. A rapid study would minimise these delays, and allow prompt
dissemination of new learning. In particular, a number of clinical questions remain unresolved, which
would be informed by a future study. Of note, it is important to establish whether or not pregnancy can
be successfully continued in women managed with ECMO. Limited evidence currently exists as to whether
or not pregnancy can be continued during and after ECMO treatment,17 but further data are needed to
fully inform management guidance and also service planning. Additionally, it will be important to
investigate whether or not the seasonal influenza immunisation current at the time of the pandemic
protects women against pandemic influenza. Immunisation policy changed subsequent to the most recent
pandemic, such that pregnant women are now offered seasonal influenza immunisation as part of a
routine programme.18 However, uptake in pregnancy remains relatively low; at the time of writing, vaccine
coverage is about 25% in pregnant women with no other complications.19 In a new pandemic situation,
establishing whether or not pregnant women have any protection from existing vaccines, as well as
establishing reasons for non-immunisation, will inform immediate public health actions.
BACKGROUND
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Chapter 2 Study objective
The objective of the project reported here was to establish, and then to put into hibernation, the studymechanisms and materials needed to mount a rapid investigation of the impact of pandemic influenza
in pregnancy in the event of a newly emerging pandemic strain. This report thus describes the study
planning and set-up phase but, as a further pandemic has not yet occurred, the study does not include any
new data on influenza in pregnancy.
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Chapter 3 Methods and results
The UK Obstetric Surveillance System (UKOSS) is a research platform to enable the study of rare orsevere complications in pregnancy.20 Reporting clinicians, who include midwives, anaesthetists and
obstetricians, are located in all 211 consultant-led maternity units in the UK. The conditions studied using
the system change over time; cases that are currently under study are reported monthly on a report card,
which is returned to the central UKOSS administration team in Oxford. The monthly card is also used to
update contact details when reporting staff change, so that the list of reporters is kept continually up to
date. When the reporting clinician indicates on the monthly card that they have a new case to report, the
UKOSS administration team will then mail out a specific data collection form. The data collection forms,
which are individually designed for each condition-specific study, contain information about a woman’s
sociodemographic, medical and pregnancy characteristics, together with information about the
management of her condition and the outcomes of pregnancy for both her and her baby. All of the
information collected is anonymous and thus can be collected without requiring women’s consent.
The UKOSS was used to conduct the UK study of pregnant women who were hospitalised with 2009
A/H1N1 influenza in the second wave of the pandemic in late 2009.13 The normal processes of UKOSS
were adapted to allow online reporting of cases and rapid return of electronic data collection forms.
Data were analysed monthly and used to inform ongoing clinical guidance.
In order to prepare a new study for a potential future pandemic of influenza, the data from the previous
study were examined, and the lead for the Pandemic Flu Planning Group at the Royal College of
Obstetricians and Gynaecologists, together with the UKOSS Steering Committee, which includes both
public and professional members, was consulted about potential unanswered questions or issues that
might be pertinent to pregnant women in future pandemics. On the basis of this consultation, the data
collection form that had been used to collect information in the 2009 pandemic was modified. New
questions were added, particularly on the use of respiratory support, including ECMO and the timing of
delivery in relation to the use of respiratory support. The data collection forms for the Influenza A/H1N1
Pandemic Study and the new study are included in Appendix 1.
The relevant regulatory approvals were obtained, a database was programmed together with a web portal
for reporting cases, and the study was hibernated pending activation in the event of a pandemic. The
authors were provided with a key contact at the funding body, who would advise activation in the event
of a pandemic.
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Chapter 4 Discussion
The UKOSS is a research platform that allows for rapid activation of studies of pregnancy complications.The set-up of this new study required very minor modifications to the data collection system that had
been set up in 2009. If regulatory approvals are facilitated, the UKOSS could be mobilised rapidly to study
pregnancy outcomes of any new emerging infection;13 we estimate that a study could be implemented
within 2–4 weeks of approvals being obtained. Advance approval, prior to any new infection emerging,
would clearly allow for even more rapid activation.
It is important to note that the UKOSS is a maternity hospital-based system; therefore, it is likely to capture
only severe pregnancy complications and outcomes, or those complications and outcomes that occur during
the same hospital admission as delivery. It will not, for example, necessarily identify women who have had an
early pregnancy loss or termination as a result of influenza or other emerging infection, as, even if they were
hospitalised, they would not necessarily be brought to the attention of maternity services. In the event of
future infections, it would therefore be beneficial also to collect information in general practice. This was
undertaken in the UK to a limited extent during the 2009 A/H1N1 influenza pandemic;5 however, it proved
much more difficult to obtain information from the community than from hospital owing to the large number
of individual reporting organisations involved. Other health systems have used routine data to identify early
pregnancy complications of 2009 A/H1N1 infection; it would be beneficial in the UK if routine systems, such
as the Clinical Practice Research Datalink (CPRD), could be used on a rapid basis to identify such complications
in the future. Additional data to be identified from general practice data could include these early pregnancy
complications, as well as hospitalisations in settings other than maternity. Although the CPRD currently covers
only a small proportion of UK general practices, if coverage is expanded, a comprehensive future study could
include both a UKOSS study and a linked study using the CPRD to collect additional information about
complications of influenza in pregnancy presenting in other settings.
Systems such as UKOSS now exist in several specialties. UKOSS was based on the model developed by the
British Paediatric Surveillance Unit (BPSU),21 and the BPSU has been successfully used to conduct studies
of emerging infections in the paediatric population, an example being new variant Creutzfeldt–Jakob
disease.22 A new system has recently been set up, covering early pregnancy units – the UK Early Pregnancy
Surveillance Service23 – and this would be a possible route to obtaining information about severe
pregnancy complications as a result of infection in the first trimester. Other systems exist in other specialty
areas, for example ophthalmology,24 paediatric surgery25 and neurology,26 all of which could be used to
investigate emerging public health threats on a rapid basis.
Robust identification of rare, but extremely severe, pregnancy complications in association with emerging
infections such as pandemic influenza can be a challenge even on a national basis, as studies will have limited
statistical power to identify such complications. The International Network of Obstetric Survey Systems27
includes member countries across Europe and Australasia, all of whom operate systems that are similar to
UKOSS. Rapid activation of a study across the entire network in a future pandemic would allow for rapid
collection and collation of information on a large number of pregnancies, thus providing information to guide
both prevention and management of infected pregnant women with the most efficiency.
It is important to note that information about the implications and outcomes of seasonal influenza in
pregnancy is incomplete. The European Centre for Disease Prevention and Control technical report
summarising the scientific advice on seasonal influenza vaccination of children and pregnant women14
identified significant gaps in the data from Europe on the burden of seasonal influenza in pregnant
women, as well as data on vaccine effectiveness and safety. The majority of the limited data available
comes from North America. The question therefore arises as to whether or not this study should be
activated in the absence of a pandemic in order to provide those data on seasonal influenza in pregnancy
for the UK. Robust UK data may further help to counsel women about the risks and benefits of influenza
vaccination, as well as aiding economic evaluation.
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Chapter 5 Conclusions
P regnant women, as a result of their altered immune system and physiology, may be uniquelysusceptible to not only influenza, but also other emerging infections. We were able to use the UKOSS
to conduct a rapid study of pregnant women who were hospitalised with 2009 influenza A/H1N1. Only
minor modifications were required to develop a study to investigate the impact and management of
influenza in pregnancy ready for activation in the event of a future pandemic. The UKOSS may be used for
rapid studies of any emerging infections in pregnancy; the conduct of studies across an international
network may allow for even more rapid information to guide advice and management in pregnancy.
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Appendix 1.1 UKOSS 2009 A/H1N1 Pandemic Influenza Study
data collection form
UK Obstetric Surveillance System
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Appendix 1.2 UKOSS new planned Pandemic Influenza Study
data collection form
CA
SE
ID Number: 
UK Obstetric Surveillance System
 
Study XX/XX
UKOSS 
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*For guidance please see back cover
Y YY Y
* (enter code, please see back cover for guidance) 
     
 No 
 cm
 
 
please go to section 3
*  No 
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CA
SE
*For guidance please see back cover
 No 
3*  No 
 No 
/ /D M Y YMD Seasonal  Pandemic 
/ /D M Y YMD Seasonal  Pandemic 
/ /D M Y YMD Seasonal  Pandemic 
/ /D M Y YMD Seasonal  Pandemic 
(tick all that apply)  
   Not known 
* / /D M Y YMD
 No 
*  No 
 No 
/ /D M Y YMD
/ /D M Y YMD
/ /D M Y YMD
/ /D M Y YMD
Headache / /D M Y YMD
/ /D M Y YMD
/ /D M Y YMD
/ /D M Y YMD
/ /D M Y YMD
/ /D M Y YMD
/ /D M Y YMD
/ /D M Y YMD
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*For guidance please see back cover
 No 
 No 
 
 
/ /D M Y YMD
 No 
/ /D M Y YMD
/ /D M Y YMD
 
 No 
 No 
/ /D M Y YMD / /D M Y YMD
/ /D M Y YMD / /D M Y YMD
(e.g. bd)
 No 
 
 No 
/ /D M Y YMD / /D M Y YMD
 No 
/ /D M Y YMD
 No 
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CA
SE
*For guidance please see back cover
 No 
/ /D M Y YMD
 No 
/ /D M Y YMD
 No 
 
 No 
 No 
If still undelivered, please complete section 6a and then go to section 7.
If the woman has delivered, please continue.
 No 
 please state indication 
 No 
 No 
/ /D M Y YMD  :h m mh
 No 
5* 
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SE
*For guidance please see back cover
 No 
 days
Or
Or
*  No 
 
 / /D M Y YMD
 No 
/ /D M Y YMD  :h m mh
(Please state if not known.) 
NB: 
/ /D M Y YMD  :h m mh
    
   
 
  Female   
 No 
 please go to section 7
 No 
 days
Or
Or
7*  No 
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CA
SE
*For guidance please see back cover
 No 
 
 No 
/ /D M Y YMD
(Please state if not known.) 
/ /D M Y YMD
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CA
SE
Pakistani
Neonatal death
Renal disease
disease
Septicaemia
Neonatal encephalopathy
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SE
UK Obstetric Surveillance System
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Project Protocol
1 Project title
Maternal and perinatal outcomes of pandemic influenza in pregnancy.
Project reference 11/46/12.
2 Planned investigation
2.1 Research objectives
a) To determine:
i) The incidence of hospitalisation with pandemic-type influenza in pregnancy.
ii) The outcomes of pandemic-type influenza in pregnancy for mother and infant.
b) To investigate:
i) The influence of demographic or pregnancy characteristics on outcomes for mother and
infant.
ii) The influence of prior immunisation with seasonal influenza vaccine or specific influenza
vaccine on outcomes for mother and infant, including an assessment of reasons for non-
immunisation.
iii) The influence of timing of delivery, particularly in relation to the use of extracorporeal
membrane oxygenation on outcomes for mother and infant.
iv) The influence of other variations in management on outcomes for mother and infant.
b) To produce guidance on the management of pandemic-type influenza infection in pregnancy
by monthly review of emerging data from this study such that outcomes for women and infants
are optimised during the pandemic.
2.2 Existing research
Evidence from the last influenza pandemic (2009/H1N1) showed that pregnant women were
particularly vulnerable to severe infection (1-5), resulting in increases in both maternal and perinatal
mortality (5-7). Further investigations, including through the UK Obstetric Surveillance System
(UKOSS) (5), highlighted specific groups of women who were at higher risk of morbidity after
2009/H1N1 infection in pregnancy. Factors associated with admission to hospital with 2009/H1N1 in
pregnancy included maternal obesity, asthma, multiparity, multiple pregnancy, black or other minority
group ethnicity and smoking among women younger than 25 years (1, 3, 5).
Active data collection on pregnant women admitted to hospital with confirmed AH1N1 influenza,
conducted using the UKOSS, as well as identifying particular subgroups of pregnant women who
were at risk of the severest disease and hence a particular target for preventive interventions, also
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pinpointed important aspects of management which resulted in improved outcomes for women,
including the importance of early antiviral treatment (5). Monthly analysis of emerging data was used
to inform ongoing clinical guidance during the pandemic. Admission to an intensive care unit, taken as
a proxy for severe morbidity, was also associated with delay in starting treatment with antiviral
medication (more than two days after the onset of symptoms) in other population studies (1, 3, 4, 8).
Most studies of 2009/H1N1 in pregnancy reported very incomplete outcomes or outcomes for only a
subset of severely affected women (table 1) (1, 3, 4, 8-10). Half of outcome rates were calculated
using subsamples of less than fifty per cent of the study cohort. The majority of studies did not follow
up women to the end of their pregnancy (3, 4, 8, 10) or in some cases the follow up time was too
short to collect outcome information on women infected at all gestations (8, 9). This approach will bias
any results towards reporting preterm births which is likely to lead to overly pessimistic results.
The UKOSS study (6) followed up 94% of the original study cohort (n=256) and demonstrated that
poor perinatal outcomes, in addition to poor maternal outcomes, were associated with 2009/H1N1
influenza infection in pregnancy. The risks of poor outcomes persisted after adjustment for maternal
and pregnancy characteristics known to be associated with poor perinatal outcomes. The study
suggested an increased risk of perinatal mortality in women infected with 2009/H1N1 compared with
the general population (perinatal mortality rate 39 per 1,000 total births (95%CI 19 to 71) compared to
7 per 1,000 total births (95%CI 3 to 13), aOR: 5.7; 95%CI 2.2 to 15.1), which was explained almost
entirely by an increased risk of stillbirth. The study was cited by the European Center for Disease as
an important European advance, strengthening the evidence for offering routine immunisation to
pregnant women in Europe (11).
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Table 1: Studies of pregnancy outcomes among 2009/H1N1 infected women
Study Study period Study population Number
of
pregnant
women
reported
Number of
women with
outcome data
(%)
Pregnancy
outcome
Number
affected
(%)
Siston 2010
(4)
14/04/2009
–
21/08/2009
Pregnant women
with 2009/H1N1
influenza, USA
788a 169 (21) Preterm
delivery
51 (30)
200 (25) Spontaneous
Abortion
8 (4)
Louie 2010
(3)
23/04/2009
–
11/08/2009
Women with
confirmed
2009/H1N1
requiring intensive
care, California,
USA
18 12 (67) Preterm
delivery
10 (83)
Hospitalised (>24
hrs) or dead women
with confirmed
2009/H1N1,
California, USA
94 37 (39) Spontaneous
Abortion
2 (5)
Creanga
2010 (8)
01/05/2009
–
30/06/2009b
Hospitilised women
with H1N1v
infection, New York,
USA
62 40 (65) Preterm
delivery
6 (15)
Neonatal
death
2 (5)
Hewagama
2010 (10)
20/05/2009
–
31/07/2009
Hospitalised
pregnant women
with 2009/H1N1
infection, Victoria,
Australia
43 15 (35) Preterm
delivery
6 (40)
24 (55) Stillbirthd/
Neonatal
death
3 (13)
ANZIC
2010 (1)
01/06/2009
–
31/08/2009
Pregnant or
recently postpartum
women admitted to
intensive care unit
with 2009/H1N1,
Australia and New
Zealand
64 61 (95) Miscarriagec 2 (3)
Stillbirthd 4 (7)
Preterm
delivery
22 (37)
Low birth
weight
18 (31)
Dubar 2010
(9)
01/08/2009
-
31/12/2009 e
Pregnant women
admitted to hospital
with confirmed
2009/H1N1, France
314 146 (46) Stillbirth 2 (1)
Loss of
pregnancy
prior to 24
weeks
4 (2)
Low birth
weight
22 (16)
Preterm birth 26 (19)
Pierce
(UKOSS)
2011 (6)
01/09/2009
-
31/01/2010
Pregnant women
admitted to hospital
with confirmed
2009/H1N1, UK
272 256 (94) Loss of
pregnancy
prior to 24
weeks
5 (2)
Stillbirth 7 (3)
Neonatal
death
3 (1)
Preterm birth 59 (24)
a Including 509 hospitalised women.
b Followed up until 18/09/2009
c Defined as in utero death <20 weeks gestation
d
e Followed up until 31/04/2010
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In addition to the mortality risk, infants were at greater risk of preterm birth (aOR 4.0, 95%CI 2.7 to
5.9). The data suggest that women with 2009/H1N1 infection who gave birth preterm were more likely
to have been infected in their third trimester. Secondary infection with pneumonia played an important
role in preterm delivery in this 2009-10 cohort; secondary pneumonia was also associated with
preterm birth in women with pandemic influenza in 1919 (12). In the UK data, the risk of preterm birth
associated with 2009/H1N1 infection persisted even after accounting for the role of secondary
pneumonia which suggests that the excess risk cannot be explained by this factor alone.
Almost half of the infants delivered preterm were delivered early because of maternal compromise.
Women are typically delivered during the third trimester in order to aid mechanical ventilation.
However, emerging evidence suggests that when women are referred for management with
extracorporeal membrane oxygenation (ECMO), in the absence of fetal compromise there may not be
an indication to deliver the fetus early (13). This is noted particularly at gestations below 30 to 32
weeks, when the size of the uterus is unlikely to affect mechanical ventilation. Increased availability
and use of ECMO may therefore have the potential to impact positively on infant outcomes even in
the presence of maternal critical illness.
Overall, these studies show a clear increase in risk of poor maternal and pregnancy outcomes in
women infected with AH1N1v influenza. Importantly, immunisation against AH1N1v influenza for
pregnant women is thus likely to have a significant impact on health outcomes for both mother and
baby. Almost half of the preterm deliveries were due to early delivery for maternal compromise,
indicating that the health of pregnant women, which is improved with rapid treatment with antiviral
agents, is an important public health priority in future waves of this and other influenza pandemics.
In a future pandemic, however, these observed patterns may differ, and a rapid study of this
susceptible group will be important to inform both ongoing preventive and management policies. In
particular, a number of clinical questions remain unresolved, which would be informed by the
proposed study. In particular, it is important to establish whether pregnancy can be successfully
continued in women managed with extracorporeal membrane oxygenation (ECMO). Anecdotal
evidence currently exists that pregnancy can be continued during and after ECMO treatment, but
further data are needed to fully inform management guidance and also service planning. Additionally
it will be important to investigate whether the current seasonal influenza immunisation at the time of
the pandemic protects women against pandemic influenza. Immunisation policy changed subsequent
to the most recent pandemic, such that pregnant women are now offered seasonal influenza
immunisation as part of a routine programme. However, uptake remains relatively low. In a new
pandemic situation, establishing whether pregnant women have any protection from existing
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vaccines, as well as establishing reasons for non-immunisation, will inform immediate public health
actions.
2.3 Research methods
2.3.1 Research Design
This will be a national prospective observational cohort study using the UK Obstetric Surveillance
System (UKOSS). UKOSS is a well-established national system to collect information about severe
maternal morbidity through more than 700 collaborating clinicians in all 222 hospitals with consultant-
led maternity units throughout the UK (see www.npeu.ox.ac.uk/ukoss for further information). All
hospitals in the UK with a consultant-led maternity unit collaborate in UKOSS, and thus it is an ideal
mechanism to collect comprehensive information about women hospitalised with pandemic influenza
in pregnancy, their management and outcomes. In view of the ethical and other difficulties of
conducting clinical trials in pregnant women, the collection of national observational data in this way
provides the best rapidly available quality evidence to inform ongoing clinical and public health policy
and management guidance. This system has been demonstrated to be able to be used to rapidly
collect information to inform policy and guidance in a previous pandemic (5, 6).
2.3.2 Cohort Identification
Cases will be identified through the UKOSS network of nominated reporting clinicians in each
consultant-led maternity unit in the UK. Nominated reporting clinicians will be asked to report all
pregnant women with confirmed pandemic influenza admitted to their unit. In view of the need for
rapid and ongoing data analysis and production of guidance, we will use a specific web-based rapid
reporting and data collection system for this study to enable UKOSS nominated clinicians to report
cases as they occur. In addition, nominated clinicians will be sent a standard UKOSS reporting card
each month to further enhance case ascertainment.
Information about comparison women will be obtained from previously collected UKOSS data. The
UKOSS database currently contains detailed demographic, pregnancy and delivery information
about a cohort of over 1500 women giving birth in the UK identified from the same hospitals as
cohort women and data collection is ongoing. Data from comparison women giving birth in the UK
in the two years prior to any future pandemic, and not reported to have been infected with
influenza, will be used to minimise any potential bias introduced by service changes, which might
be possible if an older historical comparison cohort were used.
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2.3.3 Data Gathering
On receiving a case report, the central team will ask the clinician to complete an electronic data
collection form (see appendix for draft), asking for further detailed information about women's
characteristics, diagnosis, management and outcomes. All data collected will be anonymous; no
names, addresses, postcodes, hospital or NHS numbers will be collected. Patients will be identified
using a unique UKOSS number supplied by the central team. If a completed data collection form is
not received back by the central team after three weeks, a further reminder will be sent out. If there is
still no response after a further three weeks, the clinician will be contacted by telephone.
2.3.4 Monitoring Data Collection
Information concerning pandemic influenza in pregnancy will be compared with information from the
Health Protection Agency and from the Intensive Care National Audit and Research Centre (ICNARC)
database. In addition, adult ECMO centres functioning at the time of the pandemic will be contacted
directly to identify cases. The organisation responsible for monitoring perinatal and maternal deaths
(currently under review) will also be contacted and asked to provide information on fatal cases of
pandemic influenza in pregnancy, or consequent stillbirths or neonatal deaths. If any cases are
identified through these sources which have not been identified through UKOSS, the nominated
UKOSS clinician in the relevant hospital will be contacted and asked to provide further information on
management and outcomes.
2.3.5 Study activation
UKOSS is an ongoing research system with a rolling programme of studies. Preparation of the
relevant paperwork (study protocol and data collection form) and programming, together with
obtaining UKOSS Steering Committee, ethics committee and NHS management approval in advance
(as appropriate) would allow the study to be activated very rapidly (within two weeks) in the event of a
future pandemic.
2.4 Planned inclusion/exclusion criteria
The cohort will be all pregnant women in the UK admitted to hospital with confirmed pandemic
influenza. Women not meeting the inclusion criteria will be excluded.
In order to facilitate a rapid study without placing an additional data collection burden on clinicians
in the context of an influenza pandemic, information about comparison women will be obtained
from previously collected UKOSS data. This approach was successfully used in the most recent
2009-10 influenza pandemic (5, 6). The UKOSS database currently contains detailed
demographic, pregnancy and delivery information about a cohort of over 1500 women giving birth
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
40
Project reference 11/46/12 version 2 21/03/12
Page 7 of 13
in the UK identified from the same hospitals as cohort women and data collection is ongoing. Data
from comparison women giving birth in the UK in the two years prior to any future pandemic, and
not reported to have been infected with influenza, will be used to minimise any potential bias
introduced by service changes, which might be possible if an older historical comparison cohort
were used.
The denominator population will be all women giving birth in the UK.
2.5 Ethical arrangements
This study seeks to collect anonymous information only about women who have pandemic influenza
during pregnancy. This information is key to identifying evidence to inform ongoing policy and
guidance in the context of a pandemic. The collection of information about individuals in this way
raises these main ethical issues:
1. Consent. It will not be practicable to obtain consent for data collection from individual women, as
this would prevent the achievement of the primary objective of the study, namely to document the
numbers of women who are affected in the UK. Accurate measurement of incidence requires
documentation about ALL cases occurring in the UK. The National Information Governance Board
(NIGB) Ethics and Confidentiality Committee considers that organisations seeking to use NHS
information for research purposes without consent should seek anonymised or pseudonymised
data only and not any personally identifiable information (14). Accordingly, this study will not collect
names, addresses, postcodes, dates of birth, NHS or hospital numbers. Collection of anonymised
data in this way in the absence of consent is unlikely to cause significant harm. This UKOSS
(study reference 04/MRE02/45).
2. Confidentiality and data security. In order to maintain patient confidentiality, no names,
addresses, postcodes, dates of birth, hospital or NHS numbers will be collected as outlined above.
The security of all data will be maintained by storage on a secure University network, accessible
only by the key researchers and responsible members of the University of Oxford who may require
access to data to ensure compliance with regulations. Access by any other individuals for the
purposes of any other study will only be allowed after review by the UK Obstetric Surveillance
System Steering Committee and further reference to a Research Ethics Committee. Prof Jenny
Kurinczuk, Director of the National Perinatal Epidemiology Unit, University of Oxford will act as
custodian of the data.
2.6 Proposed sample size
As the study we propose is a national observational study, the study sample size will be governed by
the disease incidence. As an estimate, based on our experience in the 2009-10 pandemic, we
anticipate identifying 300-500 infected pregnant women admitted to hospital. Information on up to
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1500 comparison women is available from existing UKOSS data. We have estimated the study size
based on estimated incidence and not any specific outcomes. However, as a guide, the table below
indicates the odds ratios detectable by a study of this size, assuming 80% power and a 5% level of
significance with a 3:1 ratio of unexposed to exposed:
Frequency of outcome in comparison cohort Odds ratio detectable by the study
1% 2.8
5% 1.8
10% 1.6
20% 1.4
2.7 Statistical analysis
The following analyses will be conducted:
a) Estimation of the incidence of hospitalisation with pandemic influenza amongst pregnant
women with 95% confidence intervals, using the denominator of total maternities in the UK
over the relevant time period.
b) Comparison of the rates of individual adverse outcomes (maternal death, level 3 critical care
unit admission, other major complication, preterm birth, congenital anomaly, stillbirth, early
neonatal death, perinatal death) between women infected with pandemic influenza admitted to
hospital and the comparison cohort. Adjustment for potential confounders will be undertaken
using Poisson regression (for rare events) or logistic regression (if the outcomes are more
frequent). Confounders included in the model will be those known to be associated with the
relevant outcomes (age, parity, marital status, ethnicity, smoking status, socioeconomic status,
previous preterm delivery, previous perinatal death).
c) The management of pregnant women hospitalised with confirmed pandemic influenza will be
described. Differences in outcomes will be explored in different subgroups according to
management. The initial subgroups examined will be as follows (although note that these may
be revised as more becomes known about the patterns of disease during the pandemic):
Antiviral treatment received within 48hr of symptom onset (Yes/No)
Type of antiviral received
Dose of antiviral received
Use of ECMO during pregnancy
Delivery prior to institution of respiratory support (Yes/No)
Mode of delivery
Guidance on the management of pregnant women with pandemic influenza in pregnancy, informed by
ongoing data analysis, will be produced and reviewed monthly with the relevant organisations, for
example, the Department of Health, Royal College of Obstetricians and Gynaecologists, Royal
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College of Midwives and Royal College of General Practitioners, in order to improve outcomes for
women and infants based on the available evidence.
2.8 Proposed outcome measures
The following outcomes will be compared between women with influenza and comparison women,
and explored in different subgroups according to management variations:
Maternal death
Maternal level 3 critical care unit admission
Other major maternal complication
Preterm birth
Congenital anomaly
Perinatal death
2.9 Research governance
Research Ethics Committee and NHS management approval will be obtained as appropriate prior to
the start of the study. The University of Oxford will act as sponsor of the study.
The overall conduct of the study will be monitored by a Management Group consisting of the Co-
Applicants, Information Scientist, Researcher, Project Programmer, Statistician and other external
members as considered necessary for the project.
3 Project timetable and milestones
3.1 Timetable
Pre-activation phase (provisional start date 1 June 2012)
June 2012 Apply for necessary approvals, develop web-based reporting systems,
finalise and format data collection form and clinician information.
Activation phase
Week 1 Study information mailed/emailed to clinicians
Week 3 Data collection commenced
Months 2-6 Ongoing reporting of new cases, data analysis, production of
management guidance and dissemination.
Months 7-10 Collection of remaining pregnancy outcome data
Month 12 Final pregnancy outcome analysis, production of guidance and
dissemination
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3.2 Milestones
Pre-activation phase
July 2012 Web-based reporting system in place, data collection form finalised and
formatted
August 2012 Approvals completed (assuming no expedited process)
Activation phase
Month 2 First data analysis, first guidance issued
Months 3-5 Ongoing monthly data analysis, revised guidance issued
Month 6 Final report on immediate maternal and pregnancy outcomes, revised guidance
Month 12 Final report on complete pregnancy outcomes, including data on pregnancy
outcomes of women undelivered at the time of interim reports
4 Expertise
The research team has the necessary expertise to carry out this comprehensive national study,
including public health (MK, JK), congenital malformations (JK), perinatal epidemiology and statistics
(MQ, MK, JK, PB), obstetric surveillance (MK), guideline development (JK, PB), and obstetrics (PO’B,
PB).
The National Perinatal Epidemiology Unit (NPEU) has a national and international reputation for
conducting studies which change policy, influence practice and improve the care of women and their
babies. MK developed and launched UKOSS and led the initiative from its inception; since its
establishment in 2005, UKOSS has generated evidence to improve prevention and management of a
range of severe pregnancy complications in the UK involving a network of over 700 collaborating
clinicians at all 222 hospitals with consultant maternity units throughout the UK. The infrastructure is
thus in place to allow rapid identification of women hospitalized with pandemic influenza infection in
pregnancy through an established active surveillance system.
PO’B is the Royal College of Obstetricians and Gynaecologists lead for pandemic influenza planning
and will provide a direct link to produce ongoing updated guidance through the RCOG pandemic
influenza planning group.
5 Service Users
Lay representatives from the UKOSS Steering Committee and Sands, the stillbirth and neonatal death
charity, have been consulted about the development and acceptability of the study protocol, data
collection form, information and other materials.
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As all data collected will be anonymous, we cannot feedback results directly to women whose data
are included in the study. The research team will therefore work directly with Sands, the stillbirth and
neonatal death charity, and the NCT (formerly National Childbirth Trust), as well as available net fora
such as Mumsnet, to ensure that results and advice are disseminated widely to pregnant women and
their partners. The NPEU has an active user and voluntary organisations advisory group through
whom dissemination will also be undertaken.
6 Flow diagram
Analysis, report and guidance
production
UK Maternity Units
Obstetricians
Midwives
Anaesthetists
Case reporting
UKOSS Admin team
Data checking and entry
UKOSS Analysis team
Study Management group
Additional case
ascertainment
HPA
ICNARC
Interim reports for reporting
clinicians
Review by relevant organisations
for inclusion in guidance
Department of Health
Royal College of Obstetricians and
Gynaecologists
Royal College of Midwives
Royal College of General
Practitioners
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